Latest Earnings Results: Q2 '26
Estimated EPS
-$0.55
Reported EPS
-$2.85
Surprise
-419.53%
Estimated Rev
$0M
Reported Rev
---
Surprise
---
Reported GAAP EPS of -$2.85 down -331.82% YoY
Bullish Takeaway
Mineralys Therapeutics, Inc. has a robust clinical foundation for its lead candidate lorundrostat, an FDA-accepted NDA, and sufficient capital to support planned operations and commercial launch through mid-2027.
Bearish Takeaway
Mineralys Therapeutics, Inc. faces substantial ongoing losses, has no product revenue, and has pledged substantially all assets as collateral under a new $500 million senior secured term loan agreement.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.58 | -- | -- | N/A |
Q2 '26 | -$0.55 | -$2.85 | -419.53% | MISSED |
Q1 '26 | -$0.47 | -$0.47 | 0.46% | BEAT |
Q4 '25 | -$0.52 | -$0.40 | 22.52% | BEAT |
Q3 '25 | -$0.61 | -$0.52 | 15.15% | BEAT |